schliessen

Filtern

 

Bibliotheken

Antitumor efficacy of liposome-encapsulated NVP-BEZ 235 in combination with irreversible electroporation

Irreversible electroporation (IRE) is an emerging minimally invasive tumor ablation technique that delivers short pulses of strong electric fields and kills cancer cells by disrupting their cell membranes with the electric pulses. However, clinical studies report that more than 10% of local tumor re... Full description

Journal Title: Drug delivery November 2018, Vol.25(1), pp.668-678
Main Author: Tian, Li
Other Authors: Qiao, Yang , Lee, Patrick , Wang, Lucas , Chang, Ashley , Ravi, Saisree , Rogers, Thomas A , Lu, Linfeng , Singhana, Burapol , Zhao, Jun , Melancon, Marites P
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: E-ISSN: 1521-0464 ; PMID: 29482386 Version:1 ; DOI: 10.1080/10717544.2018.1444683
Link: http://pubmed.gov/29482386
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: medline29482386
title: Antitumor efficacy of liposome-encapsulated NVP-BEZ 235 in combination with irreversible electroporation
format: Article
creator:
  • Tian, Li
  • Qiao, Yang
  • Lee, Patrick
  • Wang, Lucas
  • Chang, Ashley
  • Ravi, Saisree
  • Rogers, Thomas A
  • Lu, Linfeng
  • Singhana, Burapol
  • Zhao, Jun
  • Melancon, Marites P
subjects:
  • Nvp Bez-235
  • Nanoparticles
  • Cancer
  • Combination Therapy
  • Drug Delivery
  • Hepatocellular Carcinoma
  • Irreversible Electroporation (Ire)
  • Liposomes
  • Antineoplastic Agents -- Administration & Dosage
  • Imidazoles -- Administration & Dosage
  • Liposomes -- Chemistry
  • Quinolines -- Administration & Dosage
ispartof: Drug delivery, November 2018, Vol.25(1), pp.668-678
description: Irreversible electroporation (IRE) is an emerging minimally invasive tumor ablation technique that delivers short pulses of strong electric fields and kills cancer cells by disrupting their cell membranes with the electric pulses. However, clinical studies report that more than 10% of local tumor recurrences occur at the original ablated site. NVP BEZ-235 (BEZ) is a dual PI3K/mTOR inhibitor that has substantial anticancer effects. However, the clinical trials of BEZ was not satisfactory because of its low bioavailability and high toxicity, which stemmed from the use of oral administration of high doses over a long period of time. In this research, we prepared a liposomal formulation of BEZ (L-BEZ) for intratumoral injection and studied its antitumor efficacy alone and in combination with IRE. We hypothesized that IRE could release BEZ from the liposomes and that the combination could decrease tumor viability. Our results show that IRE released BEZ from its liposomal encapsulation. The combination...
language: eng
source:
identifier: E-ISSN: 1521-0464 ; PMID: 29482386 Version:1 ; DOI: 10.1080/10717544.2018.1444683
fulltext: fulltext
issn:
  • 15210464
  • 1521-0464
url: Link


@attributes
ID1279867297
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid29482386
sourceidmedline
recordidTN_medline29482386
sourceformatXML
sourcesystemPC
pqid2008885541
display
typearticle
titleAntitumor efficacy of liposome-encapsulated NVP-BEZ 235 in combination with irreversible electroporation
creatorTian, Li ; Qiao, Yang ; Lee, Patrick ; Wang, Lucas ; Chang, Ashley ; Ravi, Saisree ; Rogers, Thomas A ; Lu, Linfeng ; Singhana, Burapol ; Zhao, Jun ; Melancon, Marites P
ispartofDrug delivery, November 2018, Vol.25(1), pp.668-678
identifier
subjectNvp Bez-235 ; Nanoparticles ; Cancer ; Combination Therapy ; Drug Delivery ; Hepatocellular Carcinoma ; Irreversible Electroporation (Ire) ; Liposomes ; Antineoplastic Agents -- Administration & Dosage ; Imidazoles -- Administration & Dosage ; Liposomes -- Chemistry ; Quinolines -- Administration & Dosage
descriptionIrreversible electroporation (IRE) is an emerging minimally invasive tumor ablation technique that delivers short pulses of strong electric fields and kills cancer cells by disrupting their cell membranes with the electric pulses. However, clinical studies report that more than 10% of local tumor recurrences occur at the original ablated site. NVP BEZ-235 (BEZ) is a dual PI3K/mTOR inhibitor that has substantial anticancer effects. However, the clinical trials of BEZ was not satisfactory because of its low bioavailability and high toxicity, which stemmed from the use of oral administration of high doses over a long period of time. In this research, we prepared a liposomal formulation of BEZ (L-BEZ) for intratumoral injection and studied its antitumor efficacy alone and in combination with IRE. We hypothesized that IRE could release BEZ from the liposomes and that the combination could decrease tumor viability. Our results show that IRE released BEZ from its liposomal encapsulation. The combination...
languageeng
source
version7
lds50peer_reviewed
links
openurl$$Topenurl_article
backlink$$Uhttp://pubmed.gov/29482386$$EView_this_record_in_MEDLINE/PubMed
openurlfulltext$$Topenurlfull_article
addlink$$Uhttp://exlibris-pub.s3.amazonaws.com/aboutMedline.html$$EView_the_MEDLINE/PubMed_Copyright_Statement
search
creatorcontrib
0Tian, Li
1Qiao, Yang
2Lee, Patrick
3Wang, Lucas
4Chang, Ashley
5Ravi, Saisree
6Rogers, Thomas A
7Lu, Linfeng
8Singhana, Burapol
9Zhao, Jun
10Melancon, Marites P
titleAntitumor efficacy of liposome-encapsulated NVP-BEZ 235 in combination with irreversible electroporation
descriptionIrreversible electroporation (IRE) is an emerging minimally invasive tumor ablation technique that delivers short pulses of strong electric fields and kills cancer cells by disrupting their cell membranes with the electric pulses. However, clinical studies report that more than 10% of local tumor recurrences occur at the original ablated site. NVP BEZ-235 (BEZ) is a dual PI3K/mTOR inhibitor that has substantial anticancer effects. However, the clinical trials of BEZ was not satisfactory because of its low bioavailability and high toxicity, which stemmed from the use of oral administration of high doses over a long period of time. In this research, we prepared a liposomal formulation of BEZ (L-BEZ) for intratumoral injection and studied its antitumor efficacy alone and in combination with IRE. We hypothesized that IRE could release BEZ from the liposomes and that the combination could decrease tumor viability. Our results show that IRE released BEZ from its liposomal encapsulation. The combination...
subject
0Nvp Bez-235
1Nanoparticles
2Cancer
3Combination Therapy
4Drug Delivery
5Hepatocellular Carcinoma
6Irreversible Electroporation (Ire)
7Liposomes
8Antineoplastic Agents -- Administration & Dosage
9Imidazoles -- Administration & Dosage
10Liposomes -- Chemistry
11Quinolines -- Administration & Dosage
general
029482386
1English
2MEDLINE/PubMed (U.S. National Library of Medicine)
310.1080/10717544.2018.1444683
4MEDLINE/PubMed (NLM)
sourceidmedline
recordidmedline29482386
issn
015210464
11521-0464
rsrctypearticle
creationdate2018
addtitleDrug delivery
searchscope
0medline
1nlm_medline
2MEDLINE
scope
0medline
1nlm_medline
2MEDLINE
lsr41201811
citationpf 668 vol 25 issue 1
startdate20181101
enddate20181131
lsr30VSR-Enriched:[pqid]
sort
titleAntitumor efficacy of liposome-encapsulated NVP-BEZ 235 in combination with irreversible electroporation
authorTian, Li ; Qiao, Yang ; Lee, Patrick ; Wang, Lucas ; Chang, Ashley ; Ravi, Saisree ; Rogers, Thomas A ; Lu, Linfeng ; Singhana, Burapol ; Zhao, Jun ; Melancon, Marites P
creationdate20181100
lso0120181100
facets
frbrgroupid3940069829668265360
frbrtype5
newrecords20190701
languageeng
creationdate2018
topic
0Nvp Bez-235
1Nanoparticles
2Cancer
3Combination Therapy
4Drug Delivery
5Hepatocellular Carcinoma
6Irreversible Electroporation (Ire)
7Liposomes
8Antineoplastic Agents–Administration & Dosage
9Imidazoles–Administration & Dosage
10Liposomes–Chemistry
11Quinolines–Administration & Dosage
collectionMEDLINE/PubMed (NLM)
prefilterarticles
rsrctypearticles
creatorcontrib
0Tian, Li
1Qiao, Yang
2Lee, Patrick
3Wang, Lucas
4Chang, Ashley
5Ravi, Saisree
6Rogers, Thomas A
7Lu, Linfeng
8Singhana, Burapol
9Zhao, Jun
10Melancon, Marites P
jtitleDrug Delivery
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Tian
1Qiao
2Lee
3Wang
4Chang
5Ravi
6Rogers
7Lu
8Singhana
9Zhao
10Melancon
aufirst
0Li
1Yang
2Patrick
3Lucas
4Ashley
5Saisree
6Thomas A
7Linfeng
8Burapol
9Jun
10Marites P
au
0Tian, Li
1Qiao, Yang
2Lee, Patrick
3Wang, Lucas
4Chang, Ashley
5Ravi, Saisree
6Rogers, Thomas A
7Lu, Linfeng
8Singhana, Burapol
9Zhao, Jun
10Melancon, Marites P
atitleAntitumor efficacy of liposome-encapsulated NVP-BEZ 235 in combination with irreversible electroporation
jtitleDrug delivery
risdate201811
volume25
issue1
spage668
pages668-678
issn1071-7544
eissn1521-0464
formatjournal
genrearticle
ristypeJOUR
abstractIrreversible electroporation (IRE) is an emerging minimally invasive tumor ablation technique that delivers short pulses of strong electric fields and kills cancer cells by disrupting their cell membranes with the electric pulses. However, clinical studies report that more than 10% of local tumor recurrences occur at the original ablated site. NVP BEZ-235 (BEZ) is a dual PI3K/mTOR inhibitor that has substantial anticancer effects. However, the clinical trials of BEZ was not satisfactory because of its low bioavailability and high toxicity, which stemmed from the use of oral administration of high doses over a long period of time. In this research, we prepared a liposomal formulation of BEZ (L-BEZ) for intratumoral injection and studied its antitumor efficacy alone and in combination with IRE. We hypothesized that IRE could release BEZ from the liposomes and that the combination could decrease tumor viability. Our results show that IRE released BEZ from its liposomal encapsulation. The combination...
doi10.1080/10717544.2018.1444683
pmid29482386
date2018-11